以下文章来源于网易数读 ，作者网易数读 网易数读 . 网易旗下栏目，用数据说话。 年轻人的"甜蜜负担"。 作者 | 李台风 设计 | 秋瞳 麦土豆 来源 | 网易数读 （ID：datablog163） 不知从何时起，这届年轻人总爱把"晕碳" "控糖"挂在嘴边。 午 饭 时 稍 微 多 吃 了 两 口 米 饭 ， 眼 皮 就 重 得 像 灌 了 铅 似 的 ， 几 杯 咖 啡 下 肚 都 抵 挡 不 住 困 意。可到下午三四点，又饿得心慌，只想抓起零食小蛋糕就往嘴里塞。 本以为是牛马太久，身体难免有些小异常，就没放在心上。直至收到疑似糖尿病前期的 体检报告，顿时天都塌了，捶胸顿足，"难道人生还没开始就要结束了吗？" 事 实 上 ， 曾 被 认 为 是 爷 爷 奶 奶 们 " 专 属 " 的 糖 尿 病 ， 如 今 正 以 每 年 新 增 百 万 病 例 的 速 度 [ 1 ]，成为越来越多年轻人棘手的新世纪难题。 "老年病"，盯上年轻人 接触过糖尿病患者的人，想必知道他们的生活有多无奈——吃饭就像做数学题，得数着 米粒下咽；看别人大快朵颐，自己只能嚼菜叶子。 因"甜蜜"造成的负担，早已经成为时代流行病。2021 ...

Core Viewpoint - Junsheng Tai Pharmaceutical-B (02511) has announced that its self-developed intestinal and hepatic anti-inflammatory and metabolic regulator, HTD1801, has achieved primary efficacy endpoints and multiple secondary efficacy endpoints in two Phase 3 clinical trials for Type 2 Diabetes Mellitus (T2DM) patients [1][2]. Group 1: Clinical Trial Results - The SYMPHONY 1 and SYMPHONY 2 trials are multi-center, randomized, double-blind, placebo-controlled Phase 3 studies aimed at evaluating the efficacy and safety of HTD1801 in T2DM patients with poor blood glucose control after dietary and exercise interventions (SYMPHONY 1; N=407) and those with inadequate control on metformin (SYMPHONY 2; N=549) [2]. - The primary efficacy endpoint for both studies was the change in glycated hemoglobin (HbA1c) from baseline after 24 weeks of treatment compared to placebo, with secondary endpoints including the percentage of subjects achieving HbA1c <7.0%, fasting plasma glucose (FPG), low-density lipoprotein cholesterol (LDL-C), gamma-glutamyl transferase (GGT), and high-sensitivity C-reactive protein (hs-CRP) [2]. Group 2: Efficacy and Safety Profile - After 24 weeks of treatment, the proportion of patients achieving HbA1c <7.0% in the HTD1801 group was significantly higher than in the placebo group, with HTD1801 also showing significant reductions in both postprandial and fasting blood glucose levels [3]. - HTD1801 demonstrated the ability to lower both glucose and lipids, significantly reducing LDL-C and non-HDL-C levels, as well as inflammatory markers GGT and hs-CRP, which are closely related to cardiovascular events and clinical outcomes in T2DM patients [3]. - Both studies indicated that HTD1801 exhibited good safety and tolerability, with the most common adverse events being gastrointestinal in nature, consistent with previous clinical findings, and less than 2% of subjects discontinued due to adverse events, with no significant risk of hypoglycemia observed [3].